Zhan, L., Zhang, Y., Zeng, Q
Can IV therapy be used as preventative medicine
Aggressive simultaneous protocol (higher risk) Simultaneous start (both from week 1): Tirzepatide standard titration: Same as conservative: 2.5mg 12.5mg over 16 weeks Cagrilintide standard titration (parallel): Weeks 1-4: 0.6mg weekly Weeks 5-8: 1.2mg weekly Weeks 9-12: 1.8mg weekly Week 13+: 2.4mg weekly Aggressive dosing table: Why this is risky: Compounding side effects from start Very difficult to tolerate High dropout risk Unclear if any additional benefit Both hitting stomach simultaneously Potential maximum weight loss: 20-30% body weight (theoretical) Example: 240 lbs 168-192 lbs (48-72 lbs lost) But tolerability extremely questionable Who might attempt: Exceptional GI tolerance Prior success with GLP-1s without nausea Closely monitored by physician Willing to accept high side effect risk Can afford $1,200-2,400/month Understands experimental nature Lower cagrilintide doses with tirzepatide Moderate approach: Tirzepatide: Standard titration to 10-15mg Cagrilintide: Maximum 1.2-1.8mg (lower than standard 2.4mg) Rationale: Tirzepatide doing heavy lifting already Cagrilintide just adds amylin pathway Don't need maximum cagrilintide dose Better tolerability Significantly lower cost Moderate dosing comparison: Verdict: Lower cagrilintide doses (0.6-1.2mg) might be tolerable but benefit questionable
It promotes the development of a lighter skin tone with a smoother texture
European Neurology, 23 (5), 372-385
DHEA use to improve likelihood of IVF/ICSI success in patients with diminished ovarian reserve: A systematic review and meta-analysis
